PPARG and prostate cancer: The AR agonist DHT at nanomolar concentrations produced a significant decrease in PPARγ mRNA and protein levels within two AR-positive human prostate cancer cell lines: the castration-sensitive VCaP cells and castration-resistant C4-2 cell line (Figure 2).